Particularly, S100-A9 expression has been found to be more consistently and remarkably altered than S100-A8 in human FLT3-ITD-positive AML cell lines (MOLM13 and MOLM13-RES) after gilteritinib treatment. This evidence concerns the gene S100A8 and acute myeloid leukemia.